Market Tracker

01/18 4:44am ET

Enzo Biochem Inc (NYSE:ENZ)

6.87
Delayed Data
As of Jan 17
 -0.24 / -3.38%
Today’s Change
4.00
Today|||52-Week Range
7.51
-1.01%
Year-to-Date
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
Jan 12 / Zacks.com - Paid Partner Content
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
Jan 10 / Zacks.com - Paid Partner Content
Amgen: Phase III Data on Hyperparathyroidism Drug Published
Jan 11 / Zacks.com - Paid Partner Content
5 Small Cap ETFs and Stocks to Play January & Trump Effect
Jan 05 / Zacks.com - Paid Partner Content
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
Jan 10 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close7.11
Today’s open7.00
Day’s range6.82 - 7.09
Volume143,431
Average volume (3 months)166,374
Market cap$329.1M
Dividend yield--
Data as of 01/17/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+20.00%
Earnings growth (next 5 years)--
Revenue growth (last year)+5.30%
P/E ratio8.2
Price/Sales3.16
Price/Book3.67

Competitors

 Today’s
change
Today’s
% change
PTIProteostasis Therape...-0.36-2.80%
NVTAInvitae Corp-0.31-3.52%
RDNTRadNet Inc-0.25-4.03%
FLGTFulgent Genetics Inc-0.44-3.22%
Data as of 01/17/2017

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$102.8M
Annual profit (last year)$45.3M
Net profit margin44.06%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Executive Officer &
Secretary
Elazar Rabbani
President, CFO, Treasurer &
Class II Director
Barry W. Weiner
Corporate headquarters
New York, New York

Forecasts